BeOne Medicines AG (ONC)
Valuation Overview•Is BeOne Medicines AG Overvalued or Undervalued?
Commands a premium valuation multiple over its peers, likely pricing in superior execution.
High-quality fundamentals with a strong composite quality score of 79/100, backed by robust profitability and solvency.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street is broadly bullish, projecting solid upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
ONC demonstrates adequate business quality with stable profitability. This is backed by a fortress balance sheet, holding significant net cash ($2.5B) and minimal debt risk.
The company is driving exceptional top-line expansion (55.7% 3Y CAGR) paired with stable bottom-line earnings. The company maintains healthy operational efficiency with a 15.1% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | +40.2% | +55.7% | +76.8% | +89.8% | |
| EBITDA | $365.6M | — | — | — | — | |
| Net Income | $237.0M | +144.5% | — | — | — | |
| EPS (Diluted) | $26.65 | +624.7% | — | — | — | |
| Free Cash Flow | $595.9M | +240.6% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 88.9% | 85.5% | 84.4% | -875.1% |
| Operating Margin | 15.1% | -18.6% | -60.9% | -1240.3% |
| Net Margin | 10.7% | -15.8% | -62.6% | -1258.1% |
| FCF Margin | 20.3% | -23.8% | -69.5% | -1197.8% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q3'26Latest | $1.63 | $2.05 | +25.8% | ||
| Q2'26 | $0.73 | $1.96 | +168.5% | ||
| Q1'26 | $1.60 | $0.58 | -63.7% | ||
| Q4'25 | $0.72 | $1.09 | +51.4% | ||
| Q3'25 | $0.48 | $0.84 | +75.0% | ||
| Q2'25 | $-0.71 | $1.22 | +271.8% | ||
| Q1'25 | $-0.88 | $-1.43 | -62.5% | ||
| Q4'24 | $-0.88 | $-1.15 | -30.7% |
Total return is +21.8% (1Y), outperforming the benchmark by +8.7%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +21.4% | +10.2% | — |
| 1Y | +21.8% | +8.7% | — |
| 3YCAGR | +30.8% | +9.5% | — |
| 5YCAGR | -0.5% | -10.6% | — |
| 10YCAGR | +27.5% | +14.2% | — |
The S&P 500 is at 30.9x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about BeOne Medicines AG (ONC) valuation, health, and returns.
BeOne Medicines AG is estimated to be fairly valued under our discounted cash flow framework. relative multiples indicate the stock is Expensive versus peers compared to industry peers. trading near fair value (DCF: $0.00)
BeOne Medicines AG has multiple valuation anchors: DCF Intrinsic Value: $0.00 | Peer Relative Fair Value: $247.54 | Wall Street Analyst Target: $406.22 (implying +7.6% upside). A convergence of these signals offers higher conviction.
BeOne Medicines AG displays good financial health with a composite quality score of 79/100, supported by a Altman Z-Score of 6.2 (safe zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 18.6%.
BeOne Medicines AG does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
BeOne Medicines AG's current growth trajectory is Decelerating. The company achieved +40.2% 1Y revenue growth and +624.7% 1Y EPS growth, compared to its 3Y revenue CAGR of +55.7%.
Wall Street consensus is Buy based on 14 analysts, beating EPS expectations in 67% of recent quarters with a 2-quarter streak. The consensus price target represents a +7.6% change from current levels.
Investment risks for BeOne Medicines AG include: -31.0% 1-year max drawdown. Volatility risk is characterized by a beta of 0.82x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.